HE4 Serum Levels are Associated with Poor Prognosis in Patients with Acute Heart Failure Combined with Chronic Kidney Disease
Yi Tang,Zhengqi Hu,Zhibin Liu,Siling Peng,Tiancheng Liu,Yaoyuan Xiao,Jianqiang Peng,Hongwei Pan,Zhaofen Zheng,Jin He
DOI: https://doi.org/10.2147/ijgm.s444680
IF: 2.145
2024-04-03
International Journal of General Medicine
Abstract:Yi Tang, 1, &ast Zhengqi Hu, 2, &ast Zhibin Liu, 2 Siling Peng, 2 Tiancheng Liu, 2 Yaoyuan Xiao, 2 Jianqiang Peng, 1 Hongwei Pan, 1 Zhaofen Zheng, 1 Jin He 1 1 Department of Cardiology, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Clinical Medicine Research Center of Heart Failure of Hunan Province, Hunan Normal University, Changsha, People's Republic of China; 2 Department of Cardiology, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jin He, Email Purpose: The levels of human epididymis protein 4 (HE4) is associated not only with the prognosis of patients with acute heart failure (AHF), but also with chronic kidney disease (CKD). Our study aims to understand the prediction value of HE4 on prognosis in patients with AHF combined with CKD. Patients and Methods: This study prospectively enrolled patients diagnosed with AHF combined with CKD at the Department of Cardiology of Hunan Provincial People's Hospital from March 2019 to December 2022. Serum levels of HE4 were measured using a chemiluminescence microparticle immunoassay. The endpoint events included heart failure readmission and cardiovascular death. Results: A total of 130 patients with AHF combined with CKD were included in the stud. The median age is 73 years (interquartile range: 65– 79 years). Among the patients, 94 experienced the endpoint events. The multivariable Cox analysis reveals that LnHE4 (HR=2.280, 95% CI 1.300– 3.998, P = 0.004) and age (HR=1.024, 95% CI 1.003– 1.045, P = 0.025) are independent predictors of the endpoint events. The Kaplan-Meier survival curve demonstrates that patients with HE4 levels> 276.15 pmol/L has a significantly higher incidence of endpoint events compared to those with HE4 levels≤ 276.15 pmol/L (Log rank test: χ 2=19.689, P < 0.001). After adjusting for age and gender, the HR is 2.520 (95% CI: 1.626– 3.906, P < 0.001). Conclusion: HE4 is an independent predictor of heart failure readmission and cardiovascular death in patients with AHF combined with CKD. Keywords: Human epididymis protein 4, Acute heart failure, Chronic kidney disease, Prognosis Acute heart failure (AHF) is a severe cardiovascular condition that requires urgent treatment and intervention due to its rapid onset or progression of symptoms and signs. It may occur as a first episode (de novo) or more commonly as a result of acute decompensation of chronic heart failure. 1 The primary causes of AHF include acute myocardial damage, increased cardiac load, and arrhythmia. 2,3 AHF is significantly associated with poor prognosis in patients, with readmission rates ranging from 32% to 44% and a mortality rate of up to 30% within one year. 2,4 Approximately half of the patients with heart failure also have concurrent chronic kidney disease (CKD). The presence of CKD similarly demonstrated a significant risk of cardiovascular events. 5 As a result, it is crucial to conduct prognostic assessments of patients with AHF combined with CKD, especially, a new biomarker to evaluate the prognosis of patients with AHF combined with CKD. Currently, several biomarkers are useful for predicting the prognosis of AHF, including N-Terminal B-type natriuretic peptide (NT-proBNP), Soluble ST2 (sST2), Galectin-3 (Gal-3), and Growth differentiation factor-15 (GDF-15). 6 In clinical practice, NT-proBNP is widely used for the prognostic assessment of AHF. However, NT-proBNP levels are affected by various factors and diseases such as renal function, age, weight, pulmonary embolism, sepsis, and stroke, which can reduce its prognostic value. Particularly in patients with renal insufficiency, as NT-proBNP needs to be cleared through the kidneys, a decrease in estimated glomerular filtration rate (eGFR) can lead to an elevation in plasma NT-proBNP levels. 7 Human epididymis protein 4 (HE4), also known as WAP four-disulfide core domain 2 (WFDC2), was initially discovered in human epididymal epithelial cells and was found to be involved in sperm maturation. 8 In 2003, HE4 was identified as a biomarker for ovarian cancer. 9 Our previous research findings demonstrated that HE4 could predict the prognosis in patients with ischemic cardiomyopathy and idiopathic pulmonary hypertension with right heart failure. 10,11 In 2013, de Boer et al 12 found that HE4 levels could predict the poor prognosis in patients -Abstract Truncated-
medicine, general & internal